Nautilus Biotechnology enters $125M at-the-market equity offering with TD Cowen

Nautilus Biotechnology, Inc.

Sales agreement with TD Cowen to sell up to $125M of common stock via ATM program.
TD Cowen will receive up to 3.0% of gross proceeds as compensation.
Company may set sale parameters including price, volume, and timing; no obligation to sell.
Shares issued under S-3 registration statement filed Feb 28, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nautilus Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at $125,000,000 (effective 2024-02-28).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: $125,000,000
Effective: 2024-02-28

Exact text from the filing

On February 28, 2024, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000

View on SEC.gov

746 material agreements filed in the last 30 days. Browse all material agreements →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.